|
[1]
|
Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 2022;399(10334):1463 − 4. https://doi.org/10.1016/S0140-6736(22)00383-XCrossRef
|
|
[2]
|
Ambrosch A, Klinger A, Luber D, Arp C, Lepiorz M, Schroll S, et al. Clinical characteristics and course of infections by influenza A- and respiratory syncytial virus (RSV) in hospitalized adults. Dtsch Med Wochenschr 2018;143(9):e68 − 75. https://doi.org/10.1055/s-0044-102004CrossRef
|
|
[3]
|
Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev 2022;31(166):220105. https://doi.org/10.1183/16000617.0105-2022. |
|
[4]
|
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352(17):1749 − 59. https://doi.org/10.1056/NEJMoa043951CrossRef
|
|
[5]
|
Kurai D, Song J, Huang YC, Jie ZJ, Atanasov P, Jiang XB, et al. Targeted literature review of the burden of respiratory syncytial infection among high-risk and elderly patients in Asia Pacific region. Infect Dis Ther 2023;12(3):807 − 28. https://doi.org/10.1007/s40121-023-00777-2CrossRef
|
|
[6]
|
Ramilo O, Rodriguez-Fernandez R, Mejias A. Respiratory syncytial virus infection: old challenges and new approaches. J Infect Dis 2023;228(1):4 − 7. https://doi.org/10.1093/infdis/jiad010CrossRef
|
|
[7]
|
Laham FR, Mansbach JM, Piedra PA, Hasegawa K, Sullivan AF, Espinola JA, et al. Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis. Pediatr Infect Dis J 2017;36(8):808 − 10. https://doi.org/10.1097/INF.0000000000001596CrossRef
|
|
[8]
|
Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe 2022;3(12):e944 − 55. https://doi.org/10.1016/S2666-5247(22)00287-7CrossRef
|
|
[9]
|
Gatt D, Martin I, AlFouzan R, Moraes TJ. Prevention and treatment strategies for respiratory syncytial virus (RSV). Pathogens 2023;12(2):154. https://doi.org/10.3390/pathogens12020154CrossRef
|